Clearside Biomedical to Report Second Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, August 7, 201...
31 Julio 2019 - 3:30PM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company dedicated to developing treatments that restore and
preserve vision for people with serious eye diseases, announced
today that its second quarter 2019 financial results will be
reported on Wednesday, August 7, 2019. Management will host a
webcast and conference call at 4:30 p.m. Eastern Time to discuss
the results and provide a corporate update.
The live and archived webcast may be accessed on
the Clearside website under the Investors section: Events and
Presentations. The live call can be accessed by dialing (844)
263-8310 (domestic) or (213) 358-0959 (international) and entering
conference code: 7657547. An archive of the webcast will be
available for three months.
About Clearside Biomedical
Clearside Biomedical, Inc. is a
biopharmaceutical company dedicated to developing treatments that
restore and preserve vision for people with serious eye diseases.
Clearside’s proprietary SCS Microinjector™ targeting the
suprachoroidal space (SCS) offers unprecedented access to the back
of the eye where sight-threatening disease often occurs. The
Company’s SCS injection platform is an inherently flexible,
in-office, non-surgical procedure, intended to work with
established medications, new formulations of medicines, as well as
future therapeutic innovations such as gene therapy. Clearside is
headquartered in Alpharetta, GA. For more information, please visit
www.clearsidebio.com.
Investor and Media Contacts: Jenny Kobin Remy
Bernarda ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024